FDA hastens development of Novartis’ Kymriah in follicular lymphoma

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regenerative medicine.